HDAC9 and breast carcinoma: However, due to their toxicity and risk of overdose, HDAC inhibitors are often combined with drugs like Tamoxifen and Paclitaxel, targeting multiple oncogenic signaling pathways to overcome drug resistance in advanced breast cancer (51–53).